Gold is 2025’s best performer. UBS sees more upside
Zoetis Inc . (NYSE:ZTS), a $68 billion market cap animal health company with a "GOOD" InvestingPro Financial Health score, disclosed Monday that it has entered into an underwriting agreement for the issuance and sale of $1.85 billion in senior notes. The announcement was made in a press release statement filed with the Securities and Exchange Commission.
According to the filing, Zoetis will issue $850 million aggregate principal amount of 4.150% senior notes due 2028 and $1 billion aggregate principal amount of 5.000% senior notes due 2035. The notes were issued under an indenture dated January 28, 2013, as supplemented by a seventh supplemental indenture dated Monday, both between Zoetis and Deutsche Bank (ETR:DBKGn) Trust Company Americas, which acts as trustee. InvestingPro data shows the company operates with moderate debt levels and maintains strong cash flows to cover interest payments.
The underwriting agreement was entered into on August 11 between Zoetis and a group of underwriters represented by Barclays (LON:BARC) Capital Inc., BofA Securities, Inc., Citigroup (NYSE:C) Global Markets Inc., J.P. Morgan Securities LLC, and MUFG Securities Americas Inc.
The offering of the notes was registered on a shelf registration statement on Form S-3 (File No. 333-289241). The company’s common stock is listed on the New York Stock Exchange under the symbol ZTS.
This information is based on a press release statement included in Zoetis Inc.’s recent SEC filing.
In other recent news, Zoetis Inc. reported its second-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $1.76, compared to the forecasted $1.62. The company’s revenue also exceeded projections, reaching $2.46 billion against an anticipated $2.41 billion. UBS responded to these results by lowering its price target on Zoetis to $165 from $170, while maintaining a Neutral rating. The firm described the company’s quarterly performance as "mixed but not necessarily thesis-changing." These developments highlight recent shifts in analyst perspectives and financial outcomes for Zoetis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.